Hong Barry A, North Carol S, Pollio David E, Abbacchi Anna, Debold Christine, Adewuyi Sunday A, Lisker-Melman Mauricio
Department of Psychiatry, Washington University, School of Medicine, 660 S. Euclid Avenue, Campus Box 8134, St. Louis, MO 63110, USA.
J Clin Psychol Med Settings. 2011 Mar;18(1):99-107. doi: 10.1007/s10880-011-9227-6.
The standard of care treatment for chronic hepatitis C viral infection (HCV) is a combination of pegylated interferon alfa and ribavirin for 24-48 weeks according to the virus genotype. This therapy is known to have multiple neuropsychiatric side effects. A major concern when evaluating a patient for HCV treatment with a known history of a psychiatric disorder is the risk that the patient's psychiatric disorder will flare or become unmanageable. The possibility of precipitating depression, confusion, mania, psychosis, hallucinations, or suicidal ideation or attempt is frequently an obstacle to treatment. We present the case of a 50 year-old man with HCV and an extensive psychiatric history involving alcoholism, depression, and suicidality who participated in a psychoeducation group to help prepare him for treatment with pegylated interferon alfa/ribavirin therapy. Though the patient derived much benefit from the psychoeducation group, by the time of evaluation for HCV treatment two months after the group ended he had relapsed back into a depressive episode with suicidal thoughts. His acute psychiatric status made him unacceptable for pegylated interferon alfa/ribavirin therapy. Psychoeducation groups show promise for helping patients with chronic medical illness to be ready for and endure intensive medical treatment that has substantial psychiatric side effects. The challenge is to help patients overcome barriers to treatment, particularly psychosocial problems, because available treatments are increasingly effective.
慢性丙型肝炎病毒感染(HCV)的标准治疗方案是根据病毒基因型,联合使用聚乙二醇化干扰素α和利巴韦林,疗程为24 - 48周。已知这种疗法有多种神经精神方面的副作用。在评估有精神疾病病史的HCV患者是否适合治疗时,一个主要担忧是患者的精神疾病可能会发作或变得难以控制。引发抑郁、意识模糊、躁狂、精神病、幻觉或自杀观念或企图的可能性常常成为治疗的障碍。我们报告一例50岁男性HCV患者,其有广泛的精神病史,包括酗酒、抑郁和自杀倾向,他参加了一个心理教育小组,以帮助他为接受聚乙二醇化干扰素α/利巴韦林治疗做好准备。尽管患者从心理教育小组中获益良多,但在小组结束两个月后评估HCV治疗时,他又复发进入伴有自杀念头的抑郁发作状态。他的急性精神状态使他不适合接受聚乙二醇化干扰素α/利巴韦林治疗。心理教育小组有望帮助患有慢性疾病的患者为接受并耐受有严重精神副作用的强化医疗治疗做好准备。挑战在于帮助患者克服治疗障碍,尤其是心理社会问题,因为现有的治疗方法越来越有效。